



Perspectives From ASPR/BARDA

April Brys, PhD

Director, Division of Nonclinical Development, BARDA

Committee on the State of the Science and Future Needs for Nonhuman
Primate Model Systems

August 25, 2022

Disclaimer

The views, opinions, and/or findings expressed are those of the author and should not be interpreted as representing the official views or policies of the U.S. Department of Health and Human Services or the U.S. Government.

The BARDA Model

BARDA develops and makes available medical countermeasures (MCMs) by forming unique public-private partnerships to drive innovation off the bench to the patient to save lives.



Flexible, nimble authorities


Multi-year funding

Cutting edge expertise

Facilitate partnerships

Promote innovation

BARDA's Medical Countermeasure Development Pipeline



Nonclinical MCM Development Is Complex and Time-Consuming

- **Animal Rule Pathway** – advancement in regulatory science and ONLY pathway to licensure/approval for many MCMs
- **Challenges**
 - Understand the pathology of disease and mechanism of countermeasure
 - Using non-human models to predict human response to drugs and disease
 - Containment / capabilities (i.e. chemical / radiological)

